Compare · HYPR vs TMDX
HYPR vs TMDX
Side-by-side comparison of Hyperfine Inc. (HYPR) and TransMedics Group Inc. (TMDX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both HYPR and TMDX operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- TMDX is the larger of the two at $2.94B, about 33.7x HYPR ($87.4M).
- Over the past year, HYPR is down 31.9% and TMDX is down 25.9% - TMDX leads by 6.0 points.
- HYPR has been more active in the news (5 items in the past 4 weeks vs 2 for TMDX).
- TMDX has more recent analyst coverage (19 ratings vs 4 for HYPR).
- Company
- Hyperfine Inc.
- TransMedics Group Inc.
- Price
- -
- -
- Market cap
- $87.4M
- $2.94B
- 1M return
- -16.79%
- +1.26%
- 1Y return
- -31.88%
- -25.91%
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- 2019
- News (4w)
- 5
- 2
- Recent ratings
- 4
- 19
Hyperfine Inc.
Hyperfine, Inc. provides imaging, monitoring, and magnetic resonance imaging products. It offers Swoop Portable MR imaging system to address an unmet need in point-of-care medical imaging through a combination of hardware and software services. The company was incorporated in 2014 and is based in Guilford, Connecticut.
TransMedics Group Inc.
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG, a portable perfusion, ventilation, and monitoring system that maintains the organ at a near-physiologic state allowing physicians to assess and improve the condition of lungs between the donor and recipient sites; OCS Heart, a portable, warm perfusion, and monitoring system designed to keep a donor heart at a human-like, metabolically active state; and OCS Liver, a system that is evaluated in clinical trials for utilized and unutilized donor livers. TransMedics Group, Inc. was founded in 1998 and is headquartered in Andover, Massachusetts.
Latest HYPR
- Hyperfine, Inc. to Participate in Lake Street Capital Markets 10th Annual Best Ideas Growth Conference
- Hyperfine Builds Momentum in Year One of Neurology Office Launch with NEURO PMR Publication and More Than 3,000 Scans
- Chief Operating Officer Teisseyre Thomas sold $6,273 worth of shares (7,345 units at $0.85), decreasing direct ownership by 1% to 671,256 units (SEC Form 4) to cover withholding tax
- CFO and CAO Hale Brett sold $6,273 worth of shares (7,345 units at $0.85), decreasing direct ownership by 1% to 592,420 units (SEC Form 4) (tax withholding)
- Hyperfine Announces FDA Clearance of the Next Optive AI™ Software, Further Enhancing Image Quality, Clinical Utility, and Ease of Use of the Swoop® System Across Care Settings
- SEC Form 10-Q filed by Hyperfine Inc.
- Hyperfine Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Hyperfine, Inc. Reports Second Quarter 2026 Financial Results
- Hyperfine Announces the Release of Multiple Peer-Reviewed Publications, Expanding Clinical Evidence for the Swoop® System Across a Growing Number of Sites of Care
- Hyperfine, Inc. to Announce Second Quarter 2026 Financial Results on August 6, 2026
Latest TMDX
- TransMedics to Present at Upcoming September Investor Conferences
- Director Tobin James R gifted 18,000 shares (SEC Form 4)
- SEC Form 10-Q filed by TransMedics Group Inc.
- TransMedics Group Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- TransMedics Reports Second Quarter 2026 Financial Results
- TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
- TransMedics to Present at the Canaccord Genuity 46th Annual Growth Conference
- UBS initiated coverage on TransMedics Group with a new price target
- TransMedics to Report Second Quarter 2026 Financial Results on August 4, 2026
- Officer Corcoran Nicholas was granted 11,727 shares, increasing direct ownership by 39% to 41,558 units (SEC Form 4)